Vaccitech, the Oxford-based clinical-stage biopharmaceutical company behind the Oxford AstraZeneca vaccine, has announced the closing of its initial public offering (IPO) on the Nasdaq Global Market in the US, under the ticker symbol “VACC” on 30 April 2021. The gross proceeds from the Vaccitech IPO was approximately $110.5 million.
Vaccitech is engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. It was founded in 2016 by Professor Sarah Gilbert and Professor Adrian Hill as a spin-out from Oxford University’s Jenner Institute, one of the most prestigious vaccine centres in the world.
The company’s proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable tolerability profiles and without the ability to replicate in humans.
Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation (OUI). Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.
The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumours and viral infections and prophylactic viral vaccine programs.
Morgan Stanley, Jefferies, Barclays and William Blair acted as joint book-running managers for the offering. H.C. Wainwright & Co. acted as lead manager for the offering.
